BioCentury | Jun 28, 2019
Product Development
Why tissue-agnostic drug development needs NGS to go mainstream
...Neuregulin 1 NTRK - Neurotrophic tyrosine kinase receptor RET - Ret-proto-oncogene
Erin McCallister, Senior Editor
BLU-667
entrectinib (RG6268, rxdx-101)
Gilotrif, Giotrif, afatinib (bibw 2992, tomtovok, Tovok)
Vitrakvi...